While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the shares. BridgeBio recently announced its European partner ...

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...

BridgeBio Cardiorenal chief medical officer Dr Jonathan Fox stated: “The EU approval of acoramidis is a significant ...

Immix Biopharma (IMMX) announced that the U.S. FDA has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of ...

Recent research from Stony Brook Medicine shows that early signs of dementia are becoming more frequent among first ...

Chiefs Hall of Honor member Art Still is a proud foot soldier in the Amyloidosis Army, a nonprofit he started hoping to ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...